Disappointing results for renal denervation

The makers of the Symplicity catheter-based renal denervation device for resistant hypertension say the product will continue to be available in Australia despite negative results in a key US trial.

Medtronic announced last week that the SYMPLICITY HTN-3 trial failed to meet its primary efficacy endpoint of reducing BP in patients with uncontrolled hypertension.

The study, which followed pilot trials conducted in Australia, involved 535 patients who were

Latest

Trending